SCHEMBL4627464

SCHEMBL4627464

N=C(NCc1ccccc1)NC(=O)Cc1c(Cl)cccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.47
RAB9A P51151 1/20 0.47
AKR1B1 P15121 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
HSD17B2 P37059 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GLS O94925 1/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
PPIA P62937 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4627432 0.99 SIGMAR1 (0.46) SIGMAR1RAB9AAKR1B1CA1CA2
SCHEMBL10928503 0.81 KMT2A (0.49) AKR1B1KMT2ACYP1A2CYP3A4CYP2C19
Hydrochloric Acid SCHEMBL10929509 0.80 KMT2A (0.48) AKR1B1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL18267384 0.79 KMT2A (0.53) SIGMAR1AKR1B1KMT2ACYP3A4CYP2C19
SCHEMBL405872 0.79 CASP1 (0.50) SIGMAR1AKR1B1CA1CA2KMT2A
SCHEMBL10926992 0.79 KMT2A (0.47) AKR1B1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL439565 0.78 KMT2A (0.51) SIGMAR1AKR1B1KMT2ACYP3A4CYP2C19
SCHEMBL10308345 0.78 KMT2A (0.51) SIGMAR1RAB9AAKR1B1KMT2ACYP3A4
Hydrochloric Acid SCHEMBL10993743 0.78 KMT2A (0.46) AKR1B1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL11815149 0.77 MAPK1 (0.49) RAB9AKMT2ACYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed
EP-1032556-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE INC (US) 2005-02-02 EP disclosed
EP-1032556-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-09-06 EP disclosed
WO-1999020599-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE, INC. (US) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SIGMAR1 2799/4885RAB9A 617/4885AKR1B1 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.